- PR Newswire•8 hours ago
OTCQB: IMLFF), reported today that prior to their expiry on Friday, February 24, 2017 a total of 10,672,750 common share purchase warrants have been exercised at a price of $0.13 per common share. No commissions or placement fees have been paid related to the funds received from this warrant exercise. InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.
- CNW Group•8 hours ago
InMed Receives over $1,350,000 From Warrant Exercise
- Accesswire•11 days ago
NEW YORK, NY / ACCESSWIRE / February 16, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies is covering InMed Pharmaceuticals ...
IMLFF : Summary for INMED PHARMACEUTICAL - Yahoo Finance
InMed Pharmaceuticals Inc. (IMLFF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.29 - 0.31|
|52 Week Range||0.05 - 0.43|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-11.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|